Quantitative assessment of BCL-2: BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199)

被引：0
|
作者：
Jin, Sha [1 ]
Tapang, Paul [1 ]
Osterling, Donald J. [1 ]
Gao, Wenqing [1 ]
Albert, Daniel H. [1 ]
Souers, Andrew J. [1 ]
Leverson, Joel D. [1 ]
Phillips, Darren C. [1 ]
Chen, Jun [1 ]
机构：
[1] Abbvie Inc, N Chicago, IL USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
    Shundong Cang
    Chaitanya Iragavarapu
    John Savooji
    Yongping Song
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [2] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
    Cang, Shundong
    Iragavarapu, Chaitanya
    Savooji, John
    Song, Yongping
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [3] ABT-199: Taking Dead Aim at BCL-2
    Davids, Matthew S.
    Letai, Anthony
    CANCER CELL, 2013, 23 (02) : 139 - 141
  • [4] Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
    Matulis, Shannon
    Nooka, Ajay K.
    Von Hollen, Hayley
    Kaufman, Jonathan L.
    Lonial, Sagar
    Boise, Lawrence H.
    BLOOD, 2014, 124 (21)
  • [5] The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
    Weller, Sandra
    Toenniessen, Astrid
    Schaefer, Benjamin
    Beigl, Tobias
    Muenchow, Alina
    Bopple, Kathrin
    Hofmann, Ute
    Gillissen, Bernhard F.
    Aulitzky, Walter E.
    Kopp, Hans-Georg
    Essmann, Frank
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [6] The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
    Sandra Weller
    Astrid Toennießen
    Benjamin Schaefer
    Tobias Beigl
    Alina Muenchow
    Kathrin Böpple
    Ute Hofmann
    Bernhard F. Gillissen
    Walter E. Aulitzky
    Hans-Georg Kopp
    Frank Essmann
    Cell Death Discovery, 8
  • [7] An immunoassay detecting Bcl-2: Bim and Mcl-1: Bim complexes in the phase 1 monotherapy study of the Bcl-2 inhibitor, ABT-199/GDC-0199, in chronic lymphocytic leukemia patients
    Li, Jessica
    Chen, Jun
    Kadel, Ward
    Chyla, Brenda
    McKeegan, Evelyn
    Punnoose, Elizabeth
    Darbonne, Walter
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), in acute myeloid leukemia patients
    Popovic, Relja
    Daver, Naval
    Ruvolo, Vivian
    Chen, Ken
    Wang, Zixing
    Huang, Xin
    Mabry, Mack
    Potluri, Jalaja
    McKeegan, Evelyn
    Konopleva, Marina
    Chyla, Brenda J.
    CANCER RESEARCH, 2016, 76
  • [9] Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor, is Efficacious in Mouse Models of Lupus Nephritis and Reduces Human Lymphocyte Lifespan in vitro
    Wang, L.
    Perper, S.
    Grebe, K.
    Schwartz, A.
    Goess, C.
    O'Connor, L.
    Hartman, D.
    Westmoreland, S.
    Graff, C.
    Souers, A.
    Leverson, J.
    Elmore, S.
    Olson, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S34 - S34
  • [10] ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets
    Leverson, J.
    Souers, A.
    Boghaert, E.
    Phillips, D.
    Park, C.
    Wendt, M.
    Fairbrother, W.
    Humerickhouse, R.
    Roberts, A.
    Elmore, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 23 - 23
12345